Russell Reconstitution 2022, What Investors Should Know


The Annual Russell Index Revision and Dates to Watch (2022)

The yearly process of recasting the Russell Indexes begins on May 6, 2022, and will be complete by market opening on June 27. During the period in between, FTSE Russell will rank stocks for additions, for deletions and evaluate the companies to make sure they conform overall. The methodology for inserting and removing tickers in the Russell 3000, Russell 2000, and Russell 1000 is intentionally transparent to help eliminate price shocks. Price movements do of course occur along the way, and investors try to foresee and capitalize on them. Channelchek will be providing updates that may uncover opportunities, or at least provide an understanding of stock price swings during this period.

Background

Russell index products are widely used by institutional and retail investors throughout the world. There is more than $16 trillion currently benchmarked to a Russell index. This includes approximately $9 trillion benchmarked to the Russell US Equity indexes. The trading volume of some companies moving into an index will heighten around the last Friday in June as fund managers seek to maintain level tracking with their benchmark target. 

Opportunity

For non-passive investor money, determining which stocks may benefit from moving up to a large-cap index, down to a smaller one, or into or out of the measurements is an annual event causing volatility around stocks. There is, of course, the potential for very profitable long and short trades. And the potential for an unwitting investor to be holding a company moving out of an index, could cause less interest in the stock.

Active investors should make themselves aware of the forces at play so they may either get out of the way or become involved by taking positions with those being added or those at the end of their reign within one of the Russell measurements.

Dramatic Valuation Shifts

The leading industries and growing market-cap companies of a year ago have shifted dramatically from the reconstitution
last year
. This will be reflected in the 2022 rebalancing and is going to impact a much larger number of companies than most years. That is to say, more companies than normal will move in, out, or to another index, perhaps with amplified price movement.

The 2022 Russell Reconstitution Schedule:

• Friday, May 6 – “Rank Day” – Index membership eligibility for 2022 Russell Reconstitution determined from constituent market capitalization at market close.

• Friday, June 3 – Preliminary index additions & deletions membership lists posted to the FTSE Russell website after 6 PM US eastern time.

• Friday, June 10th & 17th – Preliminary membership lists (reflecting any updates) posted to the FTSE Russell website after 6 PM US eastern time.

• Monday, June 13 – “Lock-down” period begins with the updated membership lists published on June 17 considered to be final.

• Friday, June 24 – Russell Reconstitution is final after the close of the US equity markets.

• Monday, June 27 – Equity markets open with the newly reconstituted Russell US Indexes.

 

Take-Away

The annual reconstitution is a significant driver of dramatic shifts in some stock prices as portfolio managers have their needs shifted within a very short period of time. Longer-term demand for certain equities is altered as well. Sizable price movements and volatility are expected, especially around the last week in June. In fact, the opening day of the reconstitution is typically one of the highest trading-volume days of the year in the US equity markets.

The market event impacts more than $9 trillion of investor assets benchmarked to or invested in products based on the Russell US Indexes. Portfolio managers that are required to track one of these indexes will work to have minimal portfolio slippage away from their benchmark.  The days and weeks from May 6 through the end of June can create opportunities for investors seeking to benefit from price moves, Channelchek will be covering the event as stocks to be added to, or removed from this year’s Russell Reconstitution and other information plays out.

Be sure to register to receive Channelchek updates and information.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Content



Will Small Cap Stocks Outperform in 2022?



Small Caps are Bigger than Ever, Investors May Need to Adjust





Trump Media De-Spac in Face of Musk Twitter Purchase



No Punches Pulled at NobleCon18 Panel Discussion

 

Source

https://www.ftserussell.com/resources/russell-reconstitution

 

Stay up to date. Follow us:

 

Release – Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting



Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Research, News, and Market Data on Ocugen

MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting in Denver on May 1 – 4, 2022.

“We are excited to share information about two of the innovative treatments for blindness diseases we’ve been working on,” said Arun Upadhyay, PhD, Ocugen’s Senior Vice President of Research & Development. “Our breakthrough modifier gene therapy platform, OCU410, consisting of a RORA modifier gene, has the potential to treat patients with dry age-related macular degeneration (Dry-AMD). RORA regulates inflammatory and oxidative pathways associated with Dry-AMD and establishes homeostasis in molecular processes to control the disease pathophysiology. We believe that OCU200, our novel biologic product candidate, has the potential to offer a better therapy to millions of people with diabetic macular edema, diabetic retinopathy, and Wet-AMD, furthering our goal to provide a new option for people who are currently underserved.”

Ocugen
Presentations at ARVO 2022:

Presentation
Title:
 OCU410, a Potential Therapeutic for
Dry-AMD, Suppresses Inflammatory Cytokine Gene Expression in Retinal Pigment
Epithelial Cells

Authors: Dinesh K. Singh, Sree S. Kattala, Arun K. Upadhyay
Presentation Type: Poster Session

Presenter: Dinesh K. Singh, Principal Scientist, Discovery
Date/Time: May 1, 2022, from 12:15 – 2:15 PM MDT

Presentation
Title:
   Binding Affinity: A Measure of Potency
for OCU200, a Potential Therapeutic for the Treatment of Wet-AMD and DME

Authors: Pratap C. Naha, Subechhya Neupane, Arun K. Upadhyay.  
Presentation Type: Oral Presentation

Presenter: Pratahap C. Naha, PhD, Associate Director, Drug Delivery and Nanotechnology
Date/Time: May 4, 2022, at 3:00 PM MDT

About Dry
Age-related Macular Degenerations (Dry AMD)

Age-related Macular Degeneration (AMD) is characterized by thickening and loss of normal architecture within Bruch’s membrane, lipofuscin accumulation in the retinal pigment epithelium (“RPE”), and drusen formation beneath the RPE in Bruch’s membrane. These deposits consist of complement components, other inflammatory molecules, lipids, lipoproteins B and E, and glycoproteins. Dry AMD, which affects about 9 to 10 million Americans, involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function and central vision impairment. Dry AMD accounts for 85-90% of the total AMD population, and there is no approved treatment.

About
Diabetic Macular Edema (DME and Diabetic Retinopathy (DR)

Diabetic macular edema (DME) and diabetic retinopathy (DR) are the most common vision-threatening diseases occurring in people with diabetes. Approximately 7.7 million people are affected with DR and approximately 745,000 with DME in the United States. These numbers are expected to further increase as the number of people with diabetes increases.

About
Wet-AMD

About 10-15% of people with AMD progress to the advanced “wet” form. It’s generally caused by abnormal blood vessels that leak fluid or blood into the macula. (The part of the retina that’s responsible for central vision.) The result can be irreversible damage to photoreceptor cells and rapid, severe vision loss, particularly in the center of the field of vision, causing significant functional impairment. Wet-AMD accounts for 90% of all AMD-related blindness.

About
Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen
Contact:

Ken Inchausti
Head, Investor Relations & Communications
ken.inchausti@ocugen.com

Dealing With False Positives During Drug Screening Process


Image Credit: Alex Green (Pexels)


Discovering New Drugs is a Long and Expensive Process – Chemical Compounds that Dupe Screening Tools Make it Even Harder

Modern drug discovery is an expensive and complicated process. Hundreds of scientists and at least a decade are often required to produce a single medicine. One of the most critical steps in this process is the first one – identifying new chemical compounds that could be developed into new medicines.

Researchers rely heavily on bioassays to identify potential drug candidates. These tests measure a compound’s ability to act on a biological target of interest. Candidates that show up as a “hit” by interacting with a target of interest (such as fitting into a binding site on the target) move on to further study and development. Advances in technology called high-throughput screening have allowed researchers to run thousands of compounds through bioassays in a short time, significantly streamlining the process.

But some of these “hits” don’t actually interact with the target as intended. And for the unwary researcher, this can lead down a rabbit hole of lost time and money.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Martin Clasby, Research Assistant Professor of Medicinal Chemistry, University of Michigan.

I am a medicinal chemist who has been working in the drug discovery field for over 26 years, and one of the greatest challenges I have faced in my research is selecting good candidates from drug screening tests. One particular category of compounds, known as pan-assay interference compounds, or PAINS, is a common pitfall.

Bioassays involve placing a chemical compound together with the target of interest and measuring the strength of their interaction. Researchers assess interaction strength using a number of methods depending on how the bioassay is designed. A common assay design emits light when there is an interaction, where the intensity of the light depends upon the strength of interaction.

PAINS refer to compounds that often come up as false positives during the screening process. Because of certain characteristics of these molecules, they can interact with a target in nonspecific or unexpected ways. Some can even react chemically with the target. So while PAINS may come up as a hit in a screen, it doesn’t necessarily mean they actually do what researchers hoped they’d do. Common worst offenders include compounds like quinones, catechols and rhodanines.


Unlike desired drug compounds that interact specifically with a target of interest, PAINS react nonspecifically with a wide variety of targets. Image credit: Bcary (Wikipedia Commons)

There are a number of ways that PAINS dupe bioassays.

Some PAINS have properties that cause them to emit light (or fluoresce) under certain conditions. Since many bioassays detect light as a signal for a hit, this can confuse the assay readout and result in a false positive.

Other PAINS can act as redox cyclers in bioassays – producing hydrogen peroxide that can block the target and be misread as a hit.

Similarly, some PAINS form colloidal aggregates – clumps of molecules that interfere with the target of interest by absorbing it or modifying the molecular structure. In rare cases, these clumps can even elicit a desired interaction with the target of interest because of their large size.

Trace impurities left over from manufacturing can also elicit a PAINS response.

To make things even more complicated, because PAINS react with targets much more strongly than most compounds that are true drug candidates, PAINS often appear as the most promising hits in screening.

Curcumin, the bright yellow chemical commonly found in the turmeric in curry, is one notorious example of a pan-assay interference compound.

 

What Can be Done About PAINS?

An estimated 5% to 12% of compounds in the screening libraries academic institutions use for drug discovery consist of PAINS. Scientists misled by a false positive can waste considerable time if they try to develop these compounds into usable drugs.

Since researchers became aware of the existence of PAINS, medicinal chemists have identified frequent offenders and actively remove these compounds from screening libraries. However, some compounds will always fall through the cracks. It is ultimately up to the researcher to identify and discard these PAINS when they show up as false positives.

There are a few things researchers can do to filter out PAINS. In some cases, visually inspecting compounds for structural similarities with other known PAINS can be enough. For other cases, additional experiments are necessary to eliminate false positives.

Testing for the presence of hydrogen peroxide, for example, can help identify redox cyclers. Likewise, adding detergents can help break up colloidal aggregates. And bioassays that do not use light detection to register hits can circumvent PAINS that emit light.

Even the most experienced medicinal chemist needs to be cognizant of the dangers of these false positives. Taking steps to ensure that these types of compounds don’t make it to the next stage of drug discovery can avoid wasted time and effort and ultimately lead to a more efficient and cost-effective drug discovery process.

Suggested Reading



Psychedelic Medicine a Revolution for the Mind



A Global Reimagined Health Ecosystem





Generating Synthetic Data to Speed AI



Tracing the Origins of a Virus

 

Stay up to date. Follow us:

 

Has the Fed Run Out of Good Options?


What Will the Fed Choose: Recession or an Economic Crisis?

Last week was all about earnings, as some of Wall Street’s heavyweights released their quarterly reports. Moreover, while mixed results caused sentiment to swing from one extreme to the other, inflation remains front and center, and the outlook for Fed policy is bullish.

For example, whether it’s PepsiCo, Mondelez, or Whirlpool, companies have warned that inflation remains extremely problematic. Moreover, with American Express and Visa highlighting consumers’ eagerness to spend, the pricing pressures show no signs of slowing down. Likewise, S&P Global released its U.S. Composite PMI on Apr. 22, and I wrote on Apr. 25 that it was another all-time high for inflation.

Services:


Source: S&P Global

Manufacturing:


Source: S&P Global

With growth, employment and inflation supporting several rate hikes over the next several months, there is little in the release that implies a dovish U-turn. To that point, please remember that the survey was conducted from Apr. 11 to Apr. 21. Therefore, while investors hope that decelerating growth and inflation will allow the Fed to back off, the PMI data suggests otherwise. As such, the Fed’s conundrum continues to intensify.

Furthermore, with more appetizing earnings reports released on Apr. 28, the results were even more bullish for Fed policy. Likewise, with the precious metals (PMs’) force fields wearing off, they should suffer profoundly as rate hike volatility increases. For example, McDonald’s released its first-quarter earnings on Apr. 28. CFO Kevin Ozan said during the Q1 earnings call:

“In the U.S., I think last quarter, I mentioned that we thought commodities were going to be up roughly 8% or so for the U.S. That number is now more like 12% to 14% for the year. So U.S. commodities clearly have risen (…).”

“On the labor side, in the U.S., it’s probably over 10% right now. Part of that is because, you’ll recall that we made adjustments to our wages in our company-owned restaurants mid-year last year, so we haven’t lapped that. So part of it is due to that and part of it is due to just continued wage inflation.”

As a result, the Fed is losing control of the inflation situation, and the largest restaurant chain in the world is still sounding the alarm. Therefore, with the pricing pressures unwilling to abate on their own (which I’ve warned about for some time), killing demand is the only way to reduce the wage-price spiral.

Please see below:


Source: McDonald’s/Seeking Alpha

On top of that, Caterpillar released its first-quarter earnings on Apr. 28. For context, the company is the world’s largest construction equipment manufacturer. CFO Andrew Bonfield said during the Q1 earnings call:

“We remain encouraged by the strong demand for our products and services. The first quarter of 2022 marked the fifth consecutive quarter of higher end user demand compared to the prior year. Services remained strong in the quarter. We continue to make progress on our service initiatives, including customer value agreements, e-commerce, connected assets and prioritized service events.”

CEO Jim Umpleby added:

“Absent the supply chain constraints, our top line would have been even stronger. When the supply chain conditions ease, we expect to be well positioned to fully meet demand and gain operating leverage from higher volumes.”

Thus, with each new earnings season, companies note that demand remains resilient. As a result, why not raise prices and capitalize on too much stimulus?


Source: Caterpillar/Seeking Alpha

As expected, the “transitory” camp waved the white flag in 2022. However, the merry-go-round of input/output inflation was visible from a mile away. For example, remember what I wrote on Mar. 30, 2021?

Didn’t Powell insist that near-term inflation was only “one-time” and “transient”? Well, despite government-issued CPI data failing to capture the effect of the Fed’s liquidity circus, pricing pressures are popping up everywhere. And with corporations’ decision tree left to raising prices or accepting lower margins, which one do you think they’ll choose?

Continuing the theme, Domino’s Pizza reported its first-quarter earnings on Apr. 28. For context, the company is the largest pizza chain in the U.S. Moreover, when contrasting the quarterly results of Microsoft and Alphabet on Apr. 28, I wrote that investors fail to realize that some companies have succumbed to the medium-term realities sooner than others. Therefore, Domino’s Pizza is another example. CEO Ritch Allison said during the Q1 earnings call:

“Consistent with our communications during our prior earnings call, we faced significant inflationary cost increases across the business in Q1. Those cost pressures combined with the deleveraging from the decline in U.S. same-store sales resulted in earnings falling short of our high expectations for the business (…).”

“We believe that we will continue to face pressure both on the top line for our U.S. business and on our bottom line earnings over the next few quarters. While we remain very optimistic about our ability to drive long-term profitable growth in the near-term 2022 is shaping up to be a challenging year.”

 

CFO Sandeep Reddy added:

“In addition, we would like to update the guidance we provided in March for 2022. Based on the continuously evolving inflationary environment, we now expect the increase in the store food basket within our U.S. system to range from 10% to 12% as compared to 2021 levels.”

If that wasn’t enough, with unprecedented handouts reducing U.S. citizens’ incentive to work, staffing shortages materially impacted Domino’s Q1 results. Moreover, the development is extremely inflationary and only increases the chances of future interest rate hikes.

Please see below:


Source: Domino’s Pizza/Seeking Alpha

Therefore, while I’ve warned on numerous occasions that the Fed is in a lose-lose situation, investors still hold out hope for a dovish pivot. However, they fail to understand the consequences. For example, a dovish 180 is extremely unlikely in this environment; but even if officials completely reversed course, the long-term economic damage would be even more paramount.

When companies are saddled with input pressures, even value-oriented chains like Domino’s Pizza can only endure margin erosion for so long. Thus, with management searching for new ways to appease investors, Fed officials’ patience will only cause an even bigger long-term collapse once inflationary demand destruction unfolds.

Please see below:


Source: Domino’s Pizza/Seeking Alpha

Turning to the macroeconomic front, some interesting data also hit the wire on Apr. 28. For example, the Kansas City Fed released its Tenth District Manufacturing Survey. The headline index declined from 37 in March to 25 in April. Chad Wilkerson, Vice President and Economist at the KC Fed, said:

“The pace of regional factory growth eased somewhat but remained strong. Firms continued to report issues with higher input prices, increased supply chain disruptions, and labor shortages. However, firms were optimistic about future activity and reported little impact from higher interest rates.”

To that point, both the prices paid and received indexes increased month-over-month (MoM).

 

Please see below:


Source: KC Fed

Finally, the major surprise on Apr. 28 was that U.S. real GDP contracted by 1.4% (advance estimate) in Q1. The report stated: “The decrease in real GDP reflected decreases in private inventory investment, exports, federal government spending, and state and local government spending, while imports, which are a subtraction in the calculation of GDP, increased.”

However: “Personal consumption expenditures (PCE), nonresidential fixed investment, and residential fixed investment increased.”

Therefore, with supply chain disruptions leading to import stockpiling (which hurts GDP), net trade was the weak link. However, the dynamic should reverse in Q2 and Q3, and if so, shouldn’t impact the Fed’s rate hike cycle.

The bottom line? The Fed is stuck between a rock and a hard place: deal with inflation now and (likely) push the U.S. into a recession later or ignore inflation and watch an even bigger crisis unfold down the road. As such, the first option is the most likely outcome. Remember, while Fed officials may seem out of touch, they’re not stupid, and history shows the devastating consequences of letting unabated inflation fester. Therefore, interest rate hikes should dominate the headlines over the next several months, and the PMs and the S&P 500 should suffer mightily along the way.

In conclusion, the PMs were mixed on Apr. 28, as silver was the daily underperformer. Moreover, while mining stocks were boosted by the S&P 500, the ‘buy the dip’ crowd is fighting a losing battle. With Amazon and Apple down after the bell on Apr. 28, weak earnings guidance should also dominate the headlines in the months to come. As a result, with the USD Index on fire and real yields poised to continue their ascent, the PMs’ medium-term outlooks are extremely treacherous.

What to Watch for Next Week

With more U.S. economic data releases next week, the most important are as follows:

May 2: ISM Manufacturing PMI

Like this week’s S&P Global Report, ISM’s report is one of the most important data points because it covers growth, inflation, and employment across the entire U.S. Therefore, the results are more relevant than regional surveys.

May 3: JOLTS job openings

Since the lagged data covers March’s figures, it’s less relevant than leading data like the PMIs. However, it’s still important to monitor how government-tallied results are shaping up.

May 4: ADP private payrolls, ISM Services PMI, FOMC statement and press conference

With the FOMC poised to hike interest rates by 50 basis points on May 4, the results and Powell’s comments are the most important fundamental developments of the week. However, ADP’s private payrolls will also provide insight into the health of the U.S. labor market, while the ISM’s Services PMI will have similar implications as the manufacturing PMI. Moreover, both will provide clues about future Fed policy.

May 5: Challenger jobs cuts

With the data showcasing how many employees were fired in April, it’s another indicator of the health of the U.S. labor market.

May 6: Nonfarm payrolls, unemployment rate, average hourly earnings

Half of the Fed’s dual mandate is maximum employment, so continued strength in nonfarm payrolls is bullish for Fed policy. In addition, a low unemployment rate is also helpful, while average hourly earnings will showcase the current state of wage inflation.

All in all, economic data releases impact precious metals because they impact monetary policy. Moreover, if we continue to see higher employment and inflation, the Fed should keep its foot on the hawkish accelerator. If that occurs, the outcome is profoundly bearish for the PMs.

About the Author: Przemyslaw Radomski, CFA (PR) writes for and publishes articles that underscore his disposition of being passionately curious about markets behavior. He uses his statistical and financial background to question the common views and profit on the misconceptions.

Suggested Reading



Can the Fed Stop Inflation?



CPI and PPI Both Suggests Persistent Inflation





Deflation Not Inflation is Risk Says Cathie Wood



Will the Fed be Fighting Inflation Now?

 

Stay up to date. Follow us:

 

ACCO Brands (ACCO) – Post Call Thoughts and Updated Models

Thursday, April 28, 2022

ACCO Brands (ACCO)
Post Call Thoughts and Updated Models

ACCO Brands Corporation designs, manufactures, sources, markets, and sells office products, academic supplies, and calendar products primarily in the United States, Canada, Northern Europe, Brazil, Australia, and Mexico. It operates through three segments: ACCO Brands North America, ACCO Brands EMEA, and ACCO Brands International. The company offers office products, such as stapling, binding and laminating equipment, and related consumable supplies, as well as shredders and whiteboards; and academic products, including notebooks, folders, decorative calendars, and stationery products. It also provides private label products, as well as business machine maintenance and repair services. The company offers its business, academic, and calendar product lines under the Artline, AT-A-GLANCE, Derwent, Esselte, Five Star, GBC, Hilroy, Leitz, Marbig, Mead, NOBO, Quartet, Rapid, Rexel, Swingline, Tilibra, Wilson Jones, and other brand names. In addition, it designs, sources, distributes, markets, and sells accessories for laptop and desktop computers, and tablets comprising security products; input devices, such as presenters, mice, and trackballs; ergonomic aids, including foot and wrist rests; docking stations; and other personal computers and tablet accessories under the Kensington, Microsaver, and ClickSafe brand names. The company sells its products to consumers and commercial end-users primarily through resellers, including traditional office supply resellers, wholesalers, mass merchandisers, and retailers, as well as directly to consumers through on-line and direct mail. ACCO Brands Corporation is headquartered in Lake Zurich, Illinois.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Back-to-School. The Back-to-School season is off to a strong start. The North American market should see a strong season, while the improvement in Mexico and Brazil, neither of which are back to pre-COVID levels, should add to demand. With in-country manufacturing, we believe ACCO is well positioned to benefit if supply chain issues persist.

    Price Hikes.  Overall, ACCO still has yet to recover inflationary cost increases and we anticipate additional targeted price increases throughout all markets during the year. ACCO took a sizable price increase in EMEA on April 1 and another price increase will be taken on July 1. Hopefully, these will offset cumulative inflationary pressures in that market …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Defense Metals (DFMTF)(DEFN:CA) – Line of Sight on an Expanded and Upgraded Resource

Thursday, April 28, 2022

Defense Metals (DFMTF)(DEFN:CA)
Line of Sight on an Expanded and Upgraded Resource

Noble Capital Markets research on Defense Metals Corp. is published under ticker symbols DFMTF and DEFN:CA. The price target for DFMTF is in USD and the price target for DEFN:CA is in CAD. Defense Metals Corp. is a mineral exploration and development company focused on the acquisition, exploration and development of mineral deposits containing metals and elements commonly used in the electric power market, defense industry, national security sector and in the production of green energy technologies, such as, rare earths magnets used in wind turbines and in permanent magnet motors for electric vehicles. Defense Metals owns 100% of the Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Fall 2021 drilling program. Defense Metals released results for the final five diamond drill holes, representing 1,079 meters of drilling, associated with the company’s 29-hole, 5,349-meter diamond drill program completed during the Fall of 2021. All 29-holes yielded positive results. Drill holes WI21-57 through WI21-61 were collared from two sites within the eastern area of the Wicheeda Rare Earth Element deposit. A complete listing of drill results may be found in the company’s press release.

    Results speak for themselves.  Resource definition drill holes WI21-58 and WI21-59 yielded two of the three highest grade and width intercepts of the 2021 drill campaign. WI21-58 averaged 3.09% total rare earth oxide (TREO) over 251 meters, including 3.92% TREO over 80 meters. WI21-59 returned 2.76% TREO over 212 meters, including 3.25% TREO over 90 meters from surface. Infill drill hole WI21-60 …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Beasley Broadcast Group (BBGI) – A Path Toward Enhanced Revenue and Cash Flow Growth

Thursday, April 28, 2022

Beasley Broadcast Group (BBGI)
A Path Toward Enhanced Revenue and Cash Flow Growth

Beasley Broadcast Group Inc is a radio broadcasting company, engaged in operating radio stations throughout the United States. It operates radio stations including FM and AM radio stations located in large and mid-sized markets in the United States. The company owns and operates radio stations in the following radio markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, West Palm Beach-Boca Raton, FL, and Wilmington, DE. It is also a multi-platform, marketing solutions provider that offers on-air, online, and mobile and social media applications. The main source of revenue is the sale of advertising.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon18 highlights. Marie Tedesco, CFO, described the company’s roadmap towards an acceleration in revenue growth and higher profitability. The company plans to develop a Digital Agency business in its medium to large markets. To watch a full replay of the presentation, please click here.

    Local Radio drives growth.  Beasley’s 3 key markets, Boston, Philadelphia, and Detroit, represent over 50% of the company’s total revenues. Notably, its stations clusters have a more than 30% market share in each market. Retail and entertainment ad categories are recovering beyond pre-pandemic levels, offsetting the headwinds in auto. Additionally, a boost could come from sports betting, should …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Digerati Technologies (DTGI) – A Recipe for Accretive M & A

Thursday, April 28, 2022

Digerati Technologies (DTGI)
A Recipe for Accretive M & A

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Noblecon 18 highlights. CEO, Art Smith, highlighted a number of topics such as: the company’s roll-up strategy, diversified client base, recent acquisitions, and plans to up-list to a major exchange. The full replay of the presentation can be found here.

    Disciplined M&A strategy.  Management employs a disciplined acquisition strategy, including targeting companies on the same technology stack, in order to fast-track the integration process and maximize cost synergies. This results in Digerati typically being able to take companies with EBITDA margins of around 15% and quickly improve those margins to greater than 20% …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Orion Group Holdings (ORN) – First Look at First Quarter Results

Thursday, April 28, 2022

Orion Group Holdings (ORN)
First Look at First Quarter Results

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    1Q22. Contract revenue increased 14.1% year-over-year to $174.9 million, driven by the beginning of large jobs awarded in the second half of 2021 in the marine segment and increased cubic yard production on light commercial projects in the concrete segment. Operating loss was $2.9 million versus operating income of $2.1 million last year. Orion reported an adjusted net loss of $0.10 per share versus EPS of $0.04 a year ago.

    Marine Segment.  The Marine business generated revenue of $84.5 million in the quarter, up from $72.1 million last year. Operating income fell to $1.8 million from $2.8 million, due to a change in mix of work. The Marine segment won $25 million of work in the quarter, a win rate of 6.0% and a book-to-bill of 0.3x …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

SPACtrac Report – Forbes Global Media: A Compelling Growth Story

Thursday, April 28, 2021

Forbes Global Media: A Compelling Growth Story

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

Noblecon 18 highlights. Forbes CEO, Mike Federle, and CFO, Mike York, presented at Noblecon18, speaking on several topics, such as Forbes recent strong results and outlook for 2022, the impacts of Forbes’ brand elasticity on its growth prospects, how the company plans to leverage its in-house technology stack, a strategic investment from Binance, and when the SPAC merger is likely to close. The full video of the presentation can be found here.

2022 pacing well. Management stated that 2022 is off to a good start and expects a strong year of growth. Our full year 2022 revenue estimate is $290 million, which assumes 12% growth over 2021.

Technological advantages. During the presentation Forbes management stressed the importance of modern media companies having a strong technological foundation. Forbes has such a foundation with its analytics platform, ForbesOne, which gathers over 600 data points per user. This data allows the company to identify audience cohorts to improve content offerings as well as increase the value proposition for advertising partners.

SPAC merger update. The SPAC is expected to close by May 31. Upon the completion of the merger, shares of the SPAC (OPA) will convert to common stock of Forbes Global Media (FRBS).

Attractive valuation. Near current levels, the OPA shares trade at 9.4 times enterprise value to expected 2022 EBITDA and 7.5 times EV to expected 2023 EBITDA. Our price target of $16 represents a 60% premium to near current levels and a target EV/2022 EBITDA multiple of 16.5 times.


GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

The SPAC Company in this report is a participant in the Company Sponsored Research Program (CSRP); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Director of Research. Senior Equity Analyst specializing in Media & Entertainment. 34 years of experience as an analyst. Member of the National Cable Television Society Foundation and the National Association of Broadcasters. BS in Management Science, Computer Science Certificate and MBA specializing in Finance from St. Louis University.
Named WSJ ‘Best on the Street’ Analyst six times.
FINRA licenses 7, 24, 66, 86, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public
appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS % OF SECURITIES COVERED % IB CLIENTS
Outperform: potential return is >15% above the current price 99% 28%
Market Perform: potential return is -15% to 15% of the current price 6% 3%
Underperform: potential return is >15% below the current price 0% 0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd., Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24770

What is the VIX?



What Does it Mean When the VIX (Fear Index) is Rising or Falling?

 

Volatility is how fast stock market prices change.

The VIX, or CBOE Volatility Index is designed to be a live mathematically-based representation of expectations for stock market volatility over the next 30 days. Some investors use the VIX to measure the level of risk, fear, and/or stress in the market when making investment decisions. In general, true traders prefer high volatility, whereas ost investors prefer more predictability.

Traders can also speculate on the direction of the VIX using a variety of options and exchange-traded products.


What Does the VIX Signal?

The VIX is designed to signal the level of fear or stress in the S&P 500. This is why it’s often called the “Fear Index.”  When the VIX level is rising, it is said that market related fear is rising. A level above 30 indicates a very high level of uncertainty and fear. VIX values below 20 generally point to stable, stress-free periods in the markets.


Where Does it Come From?

The index is derived from the prices of SPX index options with near-term expiration dates, from these short options there is a calculated 30-day forward projection of volatility. Volatility is seen as a way to gauge market sentiment, and in particular, the degree of fear among market participants.

The index was created by the Chicago Board Options Exchange (CBOE) and is maintained by CBOE Global Markets. It is an important index in the world of trading and investment because it provides a quantifiable measure of market risk and investors’ sentiments.


VIX vs. S&P 500 Price

Volatility value, investors’ fear, and VIX values all move up when the market is falling. The reverse is true when the market advances – the index values, fear, and volatility decline.

The price action of the S&P 500 and the VIX often shows inverse price action: when the S&P falls sharply, the VIX rises—and vice-versa.


How to Trade the VIX

The VIX has paved the way for using volatility as a tradable asset, albeit through derivative products. Cboe launched the first VIX-based exchange-traded futures contract in March 2004, followed by the launch of VIX options in February 2006.1

 

Suggested Reading



What is a Tender Offer?



What is Fed Tightening?

 

Stay up to date. Follow us:

 

Release – Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit



Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit

Research, News, and Market Data on Tonix Pharmaceuticals

 

CHATHAM, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2022 Q2 Investor Summit on Wednesday, May 4, 2022, at 11:00 a.m. ET at the Westin New York Grand Central, New York, NY.

Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com.

About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
2TNX-2900 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
3TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
4TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. 
5TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
6TNX-102 SL is an investigational new drug and has not been approved for any indication.
7TNX-1300 is an investigational new biologic and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Release – 1-800-FLOWERS.COM Inc. Reports Results for Its Fiscal 2022 Third Quarter



1-800-FLOWERS.COM, Inc. Reports Results for Its Fiscal 2022 Third Quarter

Research, News, and Market Data on 1-800-FLOWERS.COM

 

  • Total net revenues for the quarter were $469.6 million, down 1.0 percent compared with $474.2 million in the prior year period. Compared with the Company’s fiscal 2020 third quarter, prior to the pandemic, revenues were up 68.4 percent.
  • Net loss for the quarter was $23.4 million, or a loss of $0.36 per share compared with net income of $1.4 million, or $0.02 per diluted share, in the prior year period, primarily reflecting significant year-over-year cost increases for inbound and outbound shipping, labor, and digital marketing. Adjusted net loss1 for the quarter was $21.0 million, or a loss of $0.32 per share, compared with adjusted net income1 of $1.5 million, or $0.02 per diluted share, in the prior year period.
  • Adjusted EBITDA1 for the quarter was a loss of $12.0 million, compared with adjusted EBITDA1 of $15.4 million in the prior year period.
  • Company provides revised full-year guidance including revenue growth of 3.0 percent to 5.0 percent, adjusted EBITDA in a range of $110.0 million-to-$115.0 million and adjusted EPS in a range of $0.55 -to- $0.60 per diluted share.

(1 Refer to “Definitions of Non-GAAP Financial Measures” and the tables attached at the end of this press release for a reconciliation of non-GAAP results to applicable GAAP results.)

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS), today reported results for its fiscal 2022 third quarter ended March 27, 2022.

Chris McCann, CEO of 1-800-FLOWERS.COM, Inc., said, “Our results for the fiscal third quarter were below our expectations. A solid Valentine’s Day holiday for our 1-800-Flowers brand was offset by overall slower consumer demand for everyday gifting occasions throughout the period. These results reflected a continuation, and in some areas an escalation, of the macro-economic cost headwinds that we discussed back in January at the start of the quarter, combined with slower consumer demand reflecting growing consumer concerns with rapidly rising inflation and geopolitical unrest.

“While total revenues for the quarter were essentially flat with the prior year period, they were up more than 68 percent compared with our fiscal 2020 third quarter. Over the past three years we have essentially doubled our revenues to more than 
$2 billion and we anticipate driving further growth in the current fiscal fourth quarter and for the full year by leveraging our large customer file, the strong growth we continue to see in our Celebrations Passport loyalty program – which has grown more than 40 percent since the beginning of the current fiscal year – as well as initiatives in new innovative products and partnerships,” he said.

In terms of bottom-line results, McCann said that while the Company anticipates facing continued cost headwinds in the near term, “Our strong balance sheet enables us to invest in our operating platform, including investments to automate warehouse and distribution facilities, optimize our outbound shipping operations and build and bring in inventory early. Over the longer term, we anticipate these initiatives will enable us to improve our gross margins and drive enhanced bottom-line performance.”

McCann added, “Looking ahead, the current macroeconomy is highly unpredictable, with rising inflation and other factors impacting both costs and consumer demand. However, it is important to note that we have faced challenging macro market conditions in the past and, because of the strength of our unique business platform, combined with our talented and experienced team across the enterprise, we have emerged a bigger, better, and stronger company, and we are confident that we will continue to grow our company and build shareholder value over the long term.”

Third Quarter 2022 Financial Results

Total consolidated net revenues were 
$469.6 million, down 1.0 percent compared with 
$474.2 million in the prior year period. Compared with the Company’s fiscal 2020 third quarter, prior to the pandemic, revenues were up 68.4 percent.

Gross profit margin for the quarter was 32.8 percent, a decline of 610 basis points compared with 38.9 percent in the prior year period, primarily reflecting increased costs for inbound and outbound shipping, labor, and write-offs of expired perishable inventory. Operating expenses as a percent of total revenues, improved 60 basis points to 38.4 percent of total sales, compared with 39.0 percent in the prior year period. Operating expenses, excluding stock-based compensation, the costs associated with a one-time employee class action legal settlement, and appreciation-or-depreciation of investments in the Company’s non-qualified compensation plan, improved 10 basis points to 38.1 percent of total sales, compared with 38.2 percent in the prior year period.

The combination of these factors resulted in a net loss for the quarter of 
$23.4 million, or (
$0.36) per share compared with net income of 
$1.4 million, or 
$0.02 per diluted share, in the prior year period. Adjusted net loss1 for the quarter was 
$21.0 million, or (
$0.32) per share, compared with adjusted net income1 of 
$1.5 million, or 
$0.02 per diluted share, in the prior year period. Adjusted EBITDA1 for the quarter was a loss of 
$12.0 million, compared with adjusted EBITDA1 of 
$15.4 million in the prior year period.

Segment Results:

The Company provides selected financial results for its Gourmet Foods and Gift Baskets, Consumer Floral and Gifts, and BloomNet® segments in the tables attached to this release and as follows:

  • Gourmet Foods and Gift Baskets: Revenues for the quarter were 
    $167.4 million, down 4.5 percent compared with 
    $175.2 million in the prior year period primarily reflecting the shift of the Easter holiday later into the Company’s fiscal fourth quarter as well as lower deferred revenue entering the quarter, compared with the prior year period, partly offset by higher year-over-year wholesale revenues and revenues associated with Vital Choice®, which the Company acquired in October, 2021. Gross profit margin was 25.3 percent, a decline of 1,410 basis points compared with 39.4 percent in the prior year period, primarily reflecting increased costs for labor, inbound and outbound shipping and charges associated with the write-off of expiring inventories. Segment contribution margin1 was a loss of 
    $17.1 million compared with segment contribution margin of 
    $12.1 million in the prior year period, reflecting the reduced revenues and gross margin and higher year-over-year digital marketing costs. Adjusted segment contribution margin1 for the quarter was a loss of 
    $14.2 million excluding one-time costs associated with the settlement of an employee class action lawsuit.
  • Consumer Floral and Gifts: Total revenues in this segment were 
    $264.2 million, an increase of 1.5 percent compared to 
    $260.4 million in the prior year period, primarily reflecting solid growth for the Valentine’s Day holiday partly offset by softer everyday gifting sales. Gross profit margin was 36.7 percent, down 110 basis points compared with 37.8 percent in the prior year period primarily reflecting increased shipping costs. Segment contribution margin1 was 
    $20.5 million, down 8.9 percent compared with 
    $22.5 million in the prior year period, primarily reflecting the reduced gross margin and higher year-over-year digital marketing costs.
  • BloomNet: Revenues for the quarter were 
    $38.4 million, down 1.0 percent compared with 
    $38.8 million in the prior year period. Gross profit margin was 38.7 percent, down 560 basis points, compared with 44.3 percent in the prior year period, primarily reflecting higher inbound shipping costs and product mix. As a result, segment contribution margin1 was 
    $9.8 million, down 18.8 percent compared with 
    $12.0 million in the prior year period.

Company Guidance

The Company is updating its guidance for fiscal year 2022 year reflecting reported results for the first three quarters of the year as well as its outlook for the remainder of the year. The updated guidance includes:

  • Total revenue growth of 3.0 percent to 5.0 percent, compared with the prior year;
  • Adjusted EBITDA in a range of 
    $110.0 million-to-
    $115.0 million;
  • Adjusted EPS in a range of 
    $0.55 -to- 
    $0.60 per diluted share, and;
  • The Company anticipates that Free Cash Flow for the year will be down significantly compared with the prior year based on its updated guidance and its plans to use its strong balance sheet to invest in inventory to support its growth plans and address the headwinds it sees in the macro economy.

The Company’s guidance for the year is based on several factors, including,

  • The continuing headwinds associated with the ongoing pandemic, increased costs for labor, inbound and outbound shipping and marketing, as well as consumer concerns regarding rising price inflation and geopolitical issues, somewhat offset by:
  • the Company’s ability to continue to attract new customers and add new members to its Celebrations Passport® Loyalty program, which is helping drive increased frequency, retention, and cross-category/ cross-brand purchases.

Definitions of non-GAAP Financial Measures:

We sometimes use financial measures derived from consolidated financial information, but not presented in our financial statements prepared in accordance with 
U.S. generally accepted accounting principles(“GAAP”). Certain of these are considered “non-GAAP financial measures” under the 
U.S. Securities and Exchange Commission rules. Non-GAAP financial measures referred to in this document are either labeled as “non-GAAP” or designated as such with a “1”. See below for definitions and the reasons why we use these non-GAAP financial measures. Where applicable, see the Selected Financial Information below for reconciliations of these non-GAAP measures to their most directly comparable GAAP financial measures.

EBITDA and Adjusted EBITDA:

We define EBITDA as net income (loss) before interest, taxes, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA adjusted for the impact of stock-based compensation, Non-Qualified Plan Investment appreciation/depreciation, and for certain items affecting period-to-period comparability. See Selected Financial Information for details on how EBITDA and adjusted EBITDA were calculated for each period presented. The Company presents EBITDA and adjusted EBITDA because it considers such information meaningful supplemental measures of its performance and believes such information is frequently used by the investment community in the evaluation of similarly situated companies. The Company uses EBITDA and adjusted EBITDA as factors to determine the total amount of incentive compensation available to be awarded to executive officers and other employees. The Company’s credit agreement uses EBITDA and adjusted EBITDA to determine its interest rate and to measure compliance with certain covenants. The Company also uses EBITDA and adjusted EBITDA to evaluate and price potential acquisition candidates. EBITDA and adjusted EBITDA have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of the limitations are: (a) EBITDA and adjusted EBITDA do not reflect changes in, or cash requirements for, the Company’s working capital needs; (b) EBITDA and adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on the Company’s debts; and (c) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and EBITDA does not reflect any cash requirements for such capital expenditures. EBITDA and adjusted EBITDA should only be used on a supplemental basis combined with GAAP results when evaluating the Company’s performance.

Segment Contribution Margin and Adjusted Segment Contribution Margin:

We define segment contribution margin as earnings before interest, taxes, depreciation, and amortization, before the allocation of corporate overhead expenses. Adjusted segment contribution margin is defined as segment contribution margin adjusted for certain items affecting period-to-period comparability. See Selected Financial Information for details on how segment contribution margin and adjusted segment contribution margin was calculated for each period presented. When viewed together with our GAAP results, we believe segment contribution margin and adjusted segment contribution margin provide management and users of the financial statements with meaningful information about the performance of our business segments. Segment contribution margin and adjusted segment contribution margin are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. The material limitation associated with the use of the segment contribution margin and adjusted segment contribution margin is that they are an incomplete measure of profitability as they do not include all operating expenses or non-operating income and expenses. Management compensates for these limitations when using this measure by looking at other GAAP measures, such as operating income and net income.

Adjusted Net Income (Loss) and Adjusted or Comparable Net Income (Loss) Per Common Share:

We define adjusted net income (loss) and adjusted or comparable net income (loss) per common share as net income (loss) and net income (loss) per common share adjusted for certain items affecting period-to-period comparability. See Selected Financial Information below for details on how adjusted net income (loss) and adjusted or comparable net income (loss) per common share were calculated for each period presented. We believe that adjusted net income (loss) and adjusted or comparable net income (loss) per common share are meaningful measures because they increase the comparability of period-to-period results. Since these are not measures of performance calculated in accordance with GAAP, they should not be considered in isolation of, or as a substitute for, GAAP net income (loss) and net income (loss) per common share, as indicators of operating performance and they may not be comparable to similarly titled measures employed by other companies.

Free Cash Flow:

We define free cash flow as net cash provided by operating activities less capital expenditures. The Company considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after the purchases of fixed assets, which can then be used to, among other things, invest in the Company’s business, make strategic acquisitions, strengthen the balance sheet, and repurchase stock or retire debt. Free cash flow is a liquidity measure that is frequently used by the investment community in the evaluation of similarly situated companies. Since free cash flow is not a measure of performance calculated in accordance with GAAP, it should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in the company’s cash balance for the period.

About 1-800-FLOWERS.COM, Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help customers express, connect, and celebrate. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Stock Yards® and Simply Chocolate®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad range of products and services designed to help members grow their businesses profitably; Napco?, a resource for floral gifts and seasonal décor; DesignPac Gifts, LLC, a manufacturer of gift baskets and towers; and Alice’s Table®, a lifestyle business offering fully digital livestreaming floral, culinary and other experiences to guests across the country. 1-800-FLOWERS.COM, Inc. was recognized among the top five on the National Retail Federation’s 2021 Hot 25 Retailers list, which ranks the nation’s fastest-growing retail companies. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com or follow @1800FLOWERSInc on Twitter.

FLWS-COMP / FLWS-FN

Special Note Regarding Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside of the Company’s control, which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to, statements regarding the Company’s ability to achieve its updated guidance for fiscal-year 2022; the impact of the Covid-19 pandemic on the Company; its ability to successfully integrate acquired businesses and assets; its ability to successfully execute its strategic initiatives, including its investments in its operating platform; its ability to cost-effectively acquire and retain customers; the outcome of contingencies, including legal proceedings in the normal course of business; its ability to compete against existing and new competitors; its ability to manage expenses associated with sales and marketing and necessary general and administrative and technology investments; its ability to reduce promotional activities and achieve more efficient marketing programs; and general consumer sentiment and industry and economic conditions that may affect, among other things, the levels of discretionary customer purchases of the Company’s products and the costs of shipping and labor. Reconciliations for forward looking figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including for example those related to compensation, tax items, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. The lack of such reconciling information should be considered when assessing the impact of such disclosures. The Company undertakes no obligation to publicly update any of the forward-looking statements, whether because of new information, future events or otherwise, made in this release or in any of its SEC filings. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. For a more detailed description of these and other risk factors, refer to the Company’s SEC filings, including the Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.

Conference Call:

The Company will conduct a conference call to discuss the above details and attached financial results today, Thursday, April 28, 2022, at 8:00 a.m. (ET). The conference call will be webcast live from the Investor Relations section of the Company’s website at www.1800flowersinc.com. A recording of the call will be posted on the Investor Relations section of the Company’s web site within two hours of the call’s completion. A replay of the call can be accessed beginning at 2:00 p.m. ET on the day of the call through May 5, 2022, at: (US) 1-877-344-7529; (
Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID #:5119258.

Note: The attached tables are an integral part of this press release without which the information presented in this press release should be considered incomplete.

1-800-FLOWERS.COM, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

 

 

March 27, 2022

 

 

June 27, 2021

 

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

93,025

 

 

$

173,573

 

Trade receivables, net

 

 

40,881

 

 

 

20,831

 

Inventories, net

 

 

214,444

 

 

 

153,863

 

Prepaid and other

 

 

33,506

 

 

 

51,792

 

Total current assets

 

 

381,856

 

 

 

400,059

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

230,067

 

 

 

215,287

 

Operating lease right-of-use assets

 

 

130,897

 

 

 

86,230

 

Goodwill

 

 

213,905

 

 

 

208,150

 

Other intangibles, net

 

 

146,641

 

 

 

139,048

 

Other assets

 

 

25,284

 

 

 

27,905

 

Total assets

 

$

1,128,650

 

 

$

1,076,679

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

58,502

 

 

$

57,434

 

Accrued expenses

 

 

176,551

 

 

 

178,512

 

Current maturities of long-term debt

 

 

20,000

 

 

 

20,000

 

Current portion of long-term operating lease liabilities

 

 

12,518

 

 

 

9,992

 

Total current liabilities

 

 

267,571

 

 

 

265,938

 

 

 

 

 

 

 

 

 

Long-term debt, net

 

 

147,171

 

 

 

161,512

 

Long-term operating lease liabilities

 

 

125,831

 

 

 

79,375

 

Deferred tax liabilities

 

 

32,484

 

 

 

34,162

 

Other liabilities

 

 

21,802

 

 

 

26,622

 

Total liabilities

594,859

 

 

 

567,609

 

Total stockholders’ equity

 

 

533,791

 

 

 

509,070

 

Total liabilities and stockholders’ equity

 

$

1,128,650

 

 

$

1,076,679

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

Consolidated Statements of Operations

(in thousands, except for per share data)

(unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 27,
2022

 

 

March 28,
2021

 

 

March 27,
2022

 

 

March 28,
2021

 

Net revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

E-Commerce

 

$

409,777

 

 

$

424,768

 

 

$

1,500,670

 

 

$

1,441,441

 

Other

 

 

59,799

 

 

 

49,466

 

 

 

221,323

 

 

 

193,821

 

Total net revenues

 

 

469,576

 

 

 

474,234

 

 

 

1,721,993

 

 

 

1,635,262

 

Cost of revenues

 

 

315,485

 

 

 

289,535

 

 

 

1,063,938

 

 

 

936,837

 

Gross profit

 

 

154,091

 

 

 

184,699

 

 

 

658,055

 

 

 

698,425

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and sales

 

 

130,645

 

 

 

127,923

 

 

 

432,795

 

 

 

402,904

 

Technology and development

 

 

14,456

 

 

 

14,281

 

 

 

41,369

 

 

 

39,937

 

General and administrative

 

 

22,553

 

 

 

30,912

 

 

 

78,491

 

 

 

89,960

 

Depreciation and amortization

 

 

12,693

 

 

 

11,892

 

 

 

36,251

 

 

 

31,792

 

Total operating expenses

 

 

180,347

 

 

 

185,008

 

 

 

588,906

 

 

 

564,593

 

Operating income (loss)

 

 

(26,256)

 

 

 

(309

)

 

 

69,149

 

 

 

133,832

 

Interest expense, net

 

 

1,226

 

 

 

1,553

 

 

 

4,477

 

 

 

4,520

 

Other (income) expense, net

 

 

4,007

 

 

 

(945

)

 

 

954

 

 

 

(4,201)

Income (loss) before income taxes

 

 

(31,489)

 

 

 

(917

)

 

 

63,718

 

 

 

133,513

 

Income tax expense (benefit)

 

 

(8,080)

 

 

 

(2,344

)

 

 

11,858

 

 

 

28,171

 

Net income (loss)

 

$

(23,409)

 

 

$

1,427

 

 

$

51,860

 

 

$

105,342

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income (loss) per common share

 

$

(0.36)

 

 

$

0.02

 

 

$

0.80

 

 

$

1.63

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share

 

$

(0.36)

 

 

$

0.02

 

 

$

0.79

 

 

$

1.58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in the calculation of net income (loss) per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

65,028

 

 

 

64,885

 

 

 

65,086

 

 

 

64,644

 

Diluted

 

 

65,028

 

 

 

66,474

 

 

 

65,849

 

 

 

66,564

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Nine months ended

 

 

March 27, 2022

 

March 28, 2021

 

 

 

 

 

 

Operating activities:

 

 

 

 

Net income

$

51,860

 

$

105,342

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

36,251

 

 

31,792

 

Amortization of deferred financing costs

 

943

 

 

844

 

Deferred income taxes

 

(1,678)

 

 

(2,131)

 

Bad debt expense

 

(873)

 

 

959

 

Stock-based compensation

 

6,803

 

 

8,229

 

Other non-cash items

 

1,352

 

 

(79)

 

Changes in operating items:

 

 

 

 

Trade receivables

 

(18,570)

 

 

(23,520)

 

Inventories

 

(51,928)

 

 

(7,627)

 

Prepaid and other

 

7,174

 

 

(1,301)

 

Accounts payable and accrued expenses

 

6,847

 

 

96,947

 

Other assets and liabilities

 

547

 

 

8,756

 

Net cash provided by operating activities

 

38,728

 

 

218,211

 

 

 

 

 

 

Investing activities:

 

 

 

 

Acquisitions, net of cash acquired

 

(22,105)

 

 

(250,943)

 

Capital expenditures, net of non-cash expenditures

 

(47,945)

 

 

(26,821)

 

Purchase of equity investments

 

 

 

(1,251)

 

Net cash used in investing activities

 

(70,050)

 

 

(279,015)

 

 

 

 

 

 

Financing activities:

 

 

 

 

Acquisition of treasury stock

 

(34,788)

 

 

(14,825)

 

Proceeds from exercise of employee stock options

 

846

 

 

1,596

 

Proceeds from bank borrowings

 

125,000

 

 

265,000

 

Repayment of notes payable and bank borrowings

 

(140,000)

 

 

(172,497)

 

Debt issuance cost

 

(284)

 

 

(2,193)

 

Net cash provided by (used in) financing activities

 

(49,226)

 

 

77,081

 

 

 

 

 

 

Net change in cash and cash equivalents

 

(80,548)

 

 

16,277

 

Cash and cash equivalents:

 

 

 

 

Beginning of period

 

173,573

 

 

240,506

 

End of period

$

93,025

 

$

256,783

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information – Category Information

(dollars in thousands) (unaudited)

 

 

Three Months Ended

 

March 27, 2022

Vital Choice and
Alice’s Table
Transaction Costs

 

Litigation
Settlement

As Adjusted
(non-GAAP)
March 27, 2022

March 28, 2021

%
Change

Net revenues:

 

 

 

 

 

 

 

Consumer Floral & Gifts

$

264,243

 

$

$

$

264,243

 

 

$

260,393

 

1.5

%

BloomNet

 

38,448

 

 

 

 

38,448

 

 

 

38,833

 

-1.0

%

Gourmet Foods & Gift Baskets

 

167,402

 

 

 

 

167,402

 

 

 

175,245

 

-4.5

%

Corporate

 

43

 

 

 

 

43

 

 

 

54

 

-20.4

%

Intercompany eliminations

 

(560

)

 

 

 

(560

)

 

 

(291

)

-92.4

%

Total net revenues

$

469,576

 

$

$

$

469,576

 

 

$

474,234

 

-1.0

%

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

 

Consumer Floral & Gifts

$

96,875

 

$

$

$

96,875

 

 

$

98,397

 

-1.5

%

 

 

36.7

%

 

 

 

36.7

%

 

 

37.8

%

 

 

 

 

 

 

 

 

 

BloomNet

 

14,895

 

 

 

 

14,895

 

 

 

17,194

 

-13.4

%

 

 

38.7

%

 

 

 

38.7

%

 

 

44.3

%

 

 

 

 

 

 

 

 

 

Gourmet Foods & Gift Baskets

 

42,343

 

 

 

 

42,343

 

 

 

69,091

 

-38.7

%

 

 

25.3

%

 

 

 

25.3

%

 

 

39.4

%

 

 

 

 

 

 

 

 

 

Corporate

 

(22

)

 

 

 

(22

)

 

 

17

 

-229.4

%

 

 

-51.2

%

 

 

 

-51.2

%

 

 

31.5

%

 

 

 

 

 

 

 

 

 

Total gross profit

$

154,091

 

$

$

$

154,091

 

 

$

184,699

 

-16.6

%

 

 

32.8

%

 

 

 

32.8

%

 

 

38.9

%

 

EBITDA (non-GAAP):

 

 

 

 

 

 

 

Segment Contribution Margin (non-GAAP) (a):

 

 

 

Consumer Floral & Gifts

$

20,523

 

$

$

$

20,523

 

 

$

22,537

 

-8.9

%

BloomNet

 

9,783

 

 

 

 

9,783

 

 

 

12,042

 

-18.8

%

Gourmet Foods & Gift Baskets

 

(17,134

)

 

 

2,900

 

(14,234

)

 

 

12,132

 

-217.3

%

Segment Contribution Margin Subtotal

 

13,172

 

 

 

2,900

 

16,072

 

 

 

46,711

 

-65.6

%

Corporate (b)

 

(26,735

)

 

25

 

 

(26,710

)

 

 

(35,128

)

24.0

%

EBITDA (non-GAAP)

 

(13,563

)

 

25

 

2,900

 

(10,638

)

 

 

11,583

 

-191.8

%

Add: Stock-based compensation

 

1,507

 

 

 

 

1,507

 

 

 

2,871

 

-47.5

%

Add: Compensation charge related to NQ Plan Investment

Appreciation

 

(2,881

)

 

 

 

(2,881

)

 

 

916

 

-414.5

%

Adjusted EBITDA (non-GAAP)

$

(14,937

)

$

25

$

2,900

$

(12,012

)

 

$

15,370

 

-178.2

%

 

 

 

 

 

 

 

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information – Category Information

(dollars in thousands) (unaudited)

 

Nine Months Ended

March 27,
2022

Vital Choice
and Alice’s
Table
Transaction Costs

Litigation
Settlement

As Adjusted
(non-GAAP)
March 27,
2022

March 28,
2021

Personalization
Mall Litigation
& Transaction
Costs

Harry &
David Store
Closure
Costs

As Adjusted
(non-GAAP)
March 28,
2021

%
Change

Net revenues:

Consumer Floral & Gifts

$

760,555

 

$

$

$

760,555

 

$

727,296

 

$

$

 

$

727,296

 

4.6

%

BloomNet

 

107,212

 

 

107,212

 

 

105,622

 

 

105,622

 

1.5

%

Gourmet Foods & Gift Baskets

 

855,830

 

 

855,830

 

 

803,439

 

 

803,439

 

6.5

%

Corporate

 

157

 

 

157

 

 

295

 

 

295

 

-46.8

%

Intercompany eliminations

 

(1,761

)

 

 

 

(1,761

)

 

(1,390

)

 

 

 

(1,390

)

-26.7

%

Total net revenues

$

1,721,993

 

$

$

$

1,721,993

 

$

1,635,262

 

$

$

 

$

1,635,262

 

5.3

%

Gross profit:

Consumer Floral & Gifts

$

302,903

 

$

$

$

302,903

 

$

298,457

 

$

$

 

$

298,457

 

1.5

%

 

39.8

%

 

39.8

%

 

41.0

%

 

41.0

%

 

BloomNet

 

46,325

 

 

46,325

 

 

48,852

 

 

48,852

 

-5.2

%

 

43.2

%

 

43.2

%

 

46.3

%

 

46.3

%

 

Gourmet Foods & Gift Baskets

 

308,745

 

 

308,745

 

 

350,988

 

 

350,988

 

-12.0

%

 

36.1

%

 

36.1

%

 

43.7

%

 

43.7

%

 

Corporate

 

82

 

 

82

 

 

128

 

 

128

 

-35.9

%

 

52.2

%

 

52.2

%

 

43.4

%

 

43.4

%

 

 

 

 

 

 

 

 

Total gross profit

$

658,055

 

$

$

$

658,055

 

$

698,425

 

$

$

 

$

698,425

 

-5.8

%

 

38.2

%

 

 

 

38.2

%

 

42.7

%

 

 

 

 

42.7

%

EBITDA (non-GAAP):

Segment Contribution Margin (non-GAAP) (a)

Consumer Floral & Gifts

$

77,869

 

$

$

$

77,869

 

$

87,430

 

$

$

 

$

87,430

 

-10.9

%

BloomNet

 

32,530

 

 

32,530

 

 

34,604

 

 

34,604

 

-6.0

%

Gourmet Foods & Gift Baskets

 

85,695

 

 

 

2,900

 

88,595

 

 

145,172

 

 

 

(483

)

 

144,689

 

-38.8

%

Segment Contribution Margin Subtotal

 

196,094

 

 

 

2,900

 

198,994

 

 

267,206

 

 

 

(483

)

 

266,723

 

-25.4

%

Corporate (b)

 

(90,694

)

 

540

 

 

(90,154

)

 

(101,582

)

 

5,403

 

 

(96,179

)

-6.3

%

EBITDA (non-GAAP)

 

105,400

 

 

540

 

2,900

 

108,840

 

 

165,624

 

 

5,403

 

(483

)

 

170,544

 

-36.2

%

Add: Stock-based compensation

 

6,803

 

 

6,803

 

 

8,229

 

 

8,229

 

-17.3

%

Add: Compensation charge related to NQ

Plan Investment Appreciation

 

111

 

 

111

 

 

4,123

 

 

4,123

 

-97.3

%

Adjusted EBITDA (non-GAAP)

$

112,314

 

$

540

$

2,900

$

115,754

 

$

177,976

 

$

5,403

$

(483

)

$

182,896

 

-36.7

%

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

(in thousands) (unaudited)

 

Reconciliation of net income to adjusted net income (loss) (non-GAAP):

Three Months Ended

Nine Months Ended

March 27,
2022

March 28,
2021

 

March 27,
2022

 

March 28,
2021

 

Net income (loss)

$

(23,409

)

$

1,427

$

51,860

 

$

105,342

 

Adjustments to reconcile net income (loss) to adjusted net income (loss) (non-GAAP)

Add: Transaction costs

 

25

 

 

 

540

 

 

5,403

 

Add: Litigation settlement

 

2,900

 

 

 

2,900

 

 

 

Deduct: Harry & David store closure cost adjustment

 

 

 

 

 

 

(483

)

Deduct: Income tax effect on adjustments

 

(533

)

 

79

 

(641

)

 

(1,038

)

Adjusted net income (loss) (non-GAAP)

$

(21,017

)

$

1,506

$

54,659

 

$

109,224

 

 

Basic and diluted net income (loss) per common share

Basic

$

(0.36

)

$

0.02

$

0.80

 

$

1.63

 

Diluted

$

(0.36

)

$

0.02

$

0.79

 

$

1.58

 

 
 

Basic and diluted adjusted net income (loss) per common share (non-GAAP)

Basic

$

(0.32

)

$

0.02

$

0.84

 

$

1.69

 

Diluted

$

(0.32

)

$

0.02

$

0.83

 

$

1.64

 

 

Weighted average shares used in the calculation of net income (loss) and adjusted net income (loss) per common share

Basic

 

65,028

 

 

64,885

 

65,086

 

 

64,644

 

Diluted

 

65,028

 

 

66,474

 

65,849

 

 

66,564

 

 
 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

(in thousands) (unaudited)

 

Reconciliation of net income (loss) to adjusted EBITDA (non-GAAP):

Three Months Ended

Nine Months Ended

March 27,
2022

March 28,
2021

March 27,
2022

March 28,
2021

 

Net income (loss)

$

(23,409

)

$

1,427

 

$

51,860

$

105,342

 

Add: Interest expense, net

 

5,233

 

 

608

 

 

5,431

 

319

 

Add: Depreciation and amortization

 

12,693

 

 

11,892

 

 

36,251

 

31,792

 

Add: Income tax expense (benefit)

 

(8,080

)

 

(2,344

)

 

11,858

 

28,171

 

EBITDA

 

(13,563

)

 

11,583

 

 

105,400

 

165,624

 

Add: Stock-based compensation

 

1,507

 

 

2,871

 

 

6,803

 

8,229

 

Add: Compensation charge related to NQ plan investment appreciation

 

(2,881

)

 

916

 

111

4,123

Add: Transaction costs

 

25

 

 

 

 

540

 

5,403

 

Add: Litigation settlement

 

2,900

 

 

 

 

2,900

 

(483

)

Adjusted EBITDA

$

(12,012

)

$

15,370

 

$

115,754

$

182,896

 

 
 

(a) Segment performance is measured based on segment contribution margin or segment Adjusted EBITDA, reflecting only the direct controllable revenue and operating expenses of the segments, both of which are non-GAAP measurements. As such, management’s measure of profitability for these segments does not include the effect of corporate overhead, described above, depreciation and amortization, other income (net), and other items that we do not consider indicative of our core operating performance.

 

(b) Corporate expenses consist of the Company’s enterprise shared service cost centers, and include, among other items, Information Technology, Human Resources, Accounting and Finance, Legal, Executive and Customer Service Center functions, as well as Stock-Based Compensation. In order to leverage the Company’s infrastructure, these functions are operated under a centralized management platform, providing support services throughout the organization. The costs of these functions, other than those of the Customer Service Center, which are allocated directly to the above categories based upon usage, are included within corporate expenses as they are not directly allocable to a specific segment.

 

Investor Contact:

Joseph D. Pititto

(516) 237-6131

invest@1800flowers.com



Media Contact:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.